By Connor Hart
Shares of Fulgent Genetics climbed after the company raised its outlook as it posted higher-than-expected earnings and revenue in the second quarter.
The stock jumped 15%, to $19.75, in premarket trading Friday. Through Thursday's close, shares have lost nearly one-third of their value in the past year.
The company, which runs both laboratory services and therapeutic development businesses, before the bell posted a loss of $19 million, or 62 cents a share, compared with a loss of $8.7 million, or 29 cents a share, a year earlier.
Adjusted earnings came in at 7 cents a share. Analysts surveyed by FactSet had expected an adjusted loss of 18 cents a share.
Revenue rose 15% to $81.8 million, topping the $76.2 million that Wall Street modeled.
For the year, Fulgent raised its revenue guidance by $10 million, to approximately $320 million. The El Monte, Calif., company now expects to post an adjusted loss of about 35 cents a share, compared with a prior outlook of about 65 cents a share.
Analysts are looking for an adjusted loss of 55 cents a share on revenue of $310.7 million.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 01, 2025 09:00 ET (13:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。